Evercyte showcasing latest extracellular vesicle ‘cell factories’ and revolutionary CD81 targeting at ISEV 2022 Lyon

Vienna, Austria: – Innovative biotech manufacturer Evercyte will take its customary place as a high profile scientific contributor at the Annual Meeting of the International Society of Extracellular Vesicles (ISEV 2022), this time in the French city of Lyon.

Evercyte customarily attends ISEV annual meetings, where its co-founders, Drs. Johannes and Regina Grillari, are widely recognized as leading authorities in EV and exosome research.

EV Cell Lines

Evercyte will attend ISEV 2022 as a silver sponsor and will also contribute a poster on its EV cell lines that allow scaled up production of clinical grade extracellular vesicles, including ASC/TERT300 adipose-derived MSC mesenchymal stromal cells , BM-MSC/TERT292 bone marrow- derived MSCs, P-MSC/TERT308 placental amnion-derived MSCa, and CP-MSC/TERT308 chorionic plate-derived MSCs.

The poster will explain how these cell lines have been established under xeno-free conditions, with full documentation of all manipulation steps. This supports easy transfer to cGMP facilities for generation of master cell banks that can be used for production of clinical grade vesicles.

Standardized production cell factories

The Evercyte stand at Booth 2 in the Exhibition Zone of the Lyon Convention Center will present the wider portfolio of Evercyte products and services, including cell factories for standardized production of extracellular vesicles and MSCs from adipose tissue, bone marrow, placental tissue, amniotic membrane, etc..

Displays also showcase Evercyte services such as lab-scale production of EVs from customer-derived cells, enrichment and characterization of EVs, and testing biological activity of EVs for anti-fibrotic activity, anti-inflammatory activity, neo-angiogenic activity, wound-healing activity, etc..

EV targeting via CD81 protein

Evercyte is also closely involved in a key scientific presentation   ‘Targeting of Extracellular Vesicles via de novo Antigen Binding CD81’ (OT02.06) to be delivered on the morning of Day Two of the conference (Thursday, May 26, 2022  1030-1045hrs, L’Amphithéâtre).

In this presentation, Presenting Author Dr. Madhusudhan Bobbili, of the Institute for Molecular Biotechnology, Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, and the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Vienna, will show how Evercyte has developed a proprietary technology that allows an intrinsically overrepresented protein, CD81, to serve for recognition of desired target antigen to enhance the ability of EVs in targeted delivery.

Dr. Bobbili will present this method that selects from yeast libraries displaying mutant variants of the large extracellular loop of CD81 for binders to human placental laminin, EGFR and HER2 as exemplar targets. The study confirmed specific interactions via mammalian display system with derived sequences reformatted to full-length CD81 and expressed in EVs produced by HeLa cells, HEK293 cells or HER2.

World first

A main advantage of the method is that it can rapidly deliver binders to any antigen of choice, which can simply be ‘clicked’ into the full-length CD81, recombinantly expressed on the EV surface, enabling specific EV-mediated delivery to a large variety of cells and tissues.

This is thought to be the world’s first example of harnessing an EV membrane protein as mediator of de novo target antigen recognition via in vitro molecular evolution, opening horizons to a broad range of applications in various therapeutic settings.

Evercyte GmbH supported the original study, along with Austria’s FFG-COMET- Funding Program, with Dr. Johannes Grillari as Senior Author (see Resources).

“We are delighted to be returning to ISEV once again. Their annual meetings are key events to present our products and services in the field of extracellular vesicles,” commented Dr. Johannes Grillari.

About Evercyte GmbH

Evercyte is the leading provider of immortalized human primary-like cells (‘telomerized cells’) as well as novel production cell lines for extracellular vesicles and is the partner of choice for innovative cell-based assays in the field of pharma, biotech, or cosmetic industries.

The core technology used for the establishment of these highly relevant human cell lines relies on the reactivation of the human telomerase enzyme. Besides customer-tailored cell line development as a one-stop shop, Evercyte is steadily expanding its catalog of readily available cell lines for the production of extracellular vesicles from mesenchymal stem cells using different tissues including adipose tissue, bone marrow, placenta, amnion or dental pulp.

By providing native extracellular vesicles from mesenchymal stem cells and targeting extracellular vesicles Evercyte will make a significant contribution to the development of new therapeutic approaches. Additionally, Evercyte will promote its platform technology for the generation of recombinant EVs for e.g. tissue targeting and drug targeting.

Founded in 2011, the Vienna-based company successfully pioneered the development of tools and know-how necessary for the establishment of standardized high-throughput in-vitro bioassays as well as relevant cell models and cell factories.

Learn more at: http://www.evercyte.com.

About ISEV 2022

The International Society for Extracellular Vesicles is the leading professional society for researchers and scientists involved in the study of microvesicles and exosomes.

With nearly 1,000 members, ISEV continues to be the leader in advancing the study of extracellular vesicles globally. Founded in 2012 in Sweden, ISEV is now headquartered in the USA. Through its programs and services, it provides essential training and research opportunities for those involved in exosome and microvesicle research.

The ISEV Annual Meeting attracts nearly 1,000 attendees, including top researchers in the field discussing the latest in extracellular vesicles, exosomes, and microvesicles.

ISEV 2022 is a five-day event opening May 25 at the Lyon Convention Center in southern France. .

The event is organized by ISEV, with further information at: www.eventscribe.net/2022/ISEV2022/

Resources

Click on (OT02.06) Targeting of Extracellular Vesicles via de novo Antigen Binding CD81  for detail of presentation.
Click on Evercyte Extracellular vesicles for further information.